Exchange: NASDAQ·Updated 07:34 PM EDT
IMNN logo

IMNNImunon Inc

$1.53
$0.02
(1.32%)
Today
Closed $1.53
$0.03
(1.96%)
After Hours
Mkt Cap$6.35M
Vol79,172.00
News
all
press releases
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.read more...
Benzinga
More News
Imunon (IMNN) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Exploring Imunon's Earnings Expectations
read more...
Benzinga
Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued
The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer.
Stocktwits
Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon
The data highlights promising results for IMNN-001, an IL-12 gene therapy for advanced ovarian cancer, boosting investor optimism ahead of its Phase 3 trial.
Stocktwits
Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’
Shares jumped 15.5% after hours, as retail traders pointed to “much better funding options” hinted at during the firm’s recent earnings call.
Stocktwits
<
1
>

Advertisement|Remove ads.